E.P.O.S. IASIS RESEARCH AND DEVELOPMENT LTD

Their core work

EPOS IASIS is a Cyprus-based SME specializing in biomedical computing and molecular-scale therapeutic systems. They develop autonomous nano-network and synthetic biology platforms for diagnosing and treating neurological conditions such as epilepsy and brain tumours. Their work bridges molecular communications, biosensors, and AI-driven clinical prediction to enable personalized medicine approaches. More recently, they have expanded into digital twin technology and wearable-based disease monitoring, including COVID-19 progression prediction.

What they specialise in

How they've shifted over time

EPOS IASIS entered H2020 in 2019 with a focus on physical-layer biomedical technologies — nano-networks, biophotonics, and molecular communications for brain pathology diagnostics (GLADIATOR). By 2021, their focus broadened significantly toward digital and AI-driven health tools: digital twins, edge AI, wearables, and computational drug repurposing (DIGIPREDICT), while simultaneously deepening their synthetic biology work with programmable cell circuits (PRIME). The trajectory shows a clear shift from hardware-centric biosensing toward integrated digital-biological therapeutic systems.

EPOS IASIS is converging molecular-scale therapeutics with AI-powered clinical tools, positioning itself at the intersection of synthetic biology and digital health — a space likely to attract significant future funding.

How they like to work

EPOS IASIS operates exclusively as a consortium participant, never as coordinator, which is typical for a small specialized SME contributing deep technical expertise rather than managing large projects. Across 3 projects they have worked with 20 unique partners in 12 countries, indicating they integrate well into diverse international teams rather than relying on a fixed circle. Their consistent participation in RIA (Research and Innovation Action) projects suggests they are valued for hands-on R&D contributions.

They have collaborated with 20 distinct partners across 12 European countries in just 3 projects, reflecting broad international reach relative to their size. This wide network suggests strong reputation-based recruitment into consortia rather than geographic convenience.

What sets them apart

EPOS IASIS occupies a rare niche at the intersection of molecular communications, synthetic biology, and AI-driven clinical prediction — few SMEs combine all three. Their progression from nano-network biosensing to programmable living-cell therapeutics gives them a technical depth that is unusual for a company of their size. For consortium builders, they offer a specialist who can bridge the gap between biological computing at the molecular level and digital health applications.

Highlights from their portfolio

• GLADIATOR
  Largest funding (EUR 1.1M) and most ambitious scope — autonomous, externally controllable nano-networks for brain tumour theranostics.
• PRIME
  Highly unconventional approach: a living synthetic cell computing circuit that autonomously senses and treats epilepsy and neurodegenerative diseases.
• DIGIPREDICT
  Pivoted their biomarker expertise into the digital domain — edge AI digital twins for disease progression, with COVID-19 rapid response relevance.